Pfizer Asking FDA to Approve COVID-19 Booster Shots for All Adults

November 9, 2021 by Dan McCue
Pfizer Asking FDA to Approve COVID-19 Booster Shots for All Adults
Vials of the Pfizer-BioNTech COVID-19 vaccine sit in a cooler before being thawed at a pop-up COVID-19 vaccination site in the Bronx borough of New York on Tuesday, Jan. 26, 2021. (AP Photo/Mary Altaffer, File)

WASHINGTON — Pfizer and BioNTech SE asked the Food and Drug Administration Tuesday to allow boosters of its COVID-19 vaccine for anyone 18 or older.

Currently, COVID-19 booster shots are only available to older Americans and those with underlying health conditions that make them particularly vulnerable to the virus.

In September, the FDA’s scientific advisors rejected a request to recommend extra doses of the Pfizer-BioNTech vaccine for everyone, saying it wasn’t convinced healthy young people needed one, especially when much of the world’s population remains unvaccinated.

At the same time, the agency said it would quickly expand booster shots to other adults if warranted.

In a press release, the two companies said the amendment request is based on results from a phase 3 randomized controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the vaccine.

More than 10,000 people participated in the trial, which was carried out when the Delta variant was the prevalent strain of the virus.

In October, the companies announced positive top-line results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. 

Side effects were similar to those seen with the company’s first two shots.

“Thus far, these are the first and only efficacy data disclosed from any randomized controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified,” the companies said.

A median of 11 months after their last Pfizer vaccination, trial participants were given either a third dose or a dummy shot. 

Researchers tracked any infections that occurred at least a week later, and so far have counted five cases of symptomatic COVID-19 among booster recipients compared to 109 cases among people who got dummy shots.

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue

A+
a-
  • COVID-19
  • Pfizer
  • vaccine
  • In The News

    Health

    Voting

    Health

    Biden Announcing New Rule to Protect Consumers Who Purchase Short-Term Health Insurance Plans

    President Joe Biden on Thursday announced new steps to protect consumers who buy short-term health insurance plans that critics say amount to junk. A... Read More

    President Joe Biden on Thursday announced new steps to protect consumers who buy short-term health insurance plans that critics say amount to junk. A new rule finalized by the Democratic president's administration will limit these plans to just three months. And the plans can only be renewed for a maximum... Read More

    March 27, 2024
    by Dan McCue
    One-Time Treatment Could Revitalize Immune Systems in the Elderly

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of... Read More

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of immune cell could potentially revitalize the immune systems of the elderly, helping their bodies better react to viral and bacterial threats. The research was carried out... Read More

    March 27, 2024
    by Dan McCue
    Insurers to Expand Access to ‘Navigation Services’ for Cancer Patients

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients... Read More

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients and their families navigate the myriad challenges that might arise during treatment for cancer and other serious illnesses. The insurers involved are Aetna; Blue Cross Blue... Read More

    Five Takeaways From the Abortion Pill Case Before US Supreme Court

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone,... Read More

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration. It's... Read More

    Biden and Harris Argue Democrats Will Preserve Health Care and Republicans Would Take It Away

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in... Read More

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in the battleground state of North Carolina, arguing that Democrats like themselves would preserve access to care while Republicans would reverse gains made over the past decade... Read More

    March 26, 2024
    by Tom Ramstack
    Supreme Court Skeptical of Ban on Abortion Pill Mifepristone

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access... Read More

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access to the abortion pill mifepristone despite objections from anti-abortion activists. The doctors and organizations who sued argued the Food and Drug Administration was wrong in granting... Read More

    News From The Well
    scroll top